Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function

Toxicological sciences : an official journal of the Society of Toxicology

Volumn 140, Issue 2, 2014, Pages 470-480

  Gelzleichter, Thomas R ^a   Halpern, Wendy ^a   Erwin, Roy ^a   Baruch, Amos ^a   Leabman, Maya ^a   Forrest, Abigail S ^a   Satterwhite, Christina M ^a   Peng, Kun ^a   Chilton, Jennifer ^a   Stevens, Dale ^a  

^a GENENTECH INC   (United States)

Author keywords

atorvastatin; immunotoxicology; nonhuman primate; PCSK9; therapeutic monoclonal antibody

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PYRROLE DERIVATIVE; RECOMBINANT PROTEIN; SERINE PROTEINASE;

ANIMAL; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNOLOGY; MACACA FASCICULARIS; MALE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; FEMALE; HEPTANOIC ACIDS; HYPERSENSITIVITY, DELAYED; MACACA FASCICULARIS; MALE; PROPROTEIN CONVERTASES; PYRROLES; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES;

EID: 84925884013     PISSN: None     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu093     Document Type: Article

References (0)